Vanilla X. Zhang

LKS Faculty Of Medicine
Hong Kong, HCW, Hong Kong Special Administrative Region

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Correction: Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma.

Correction: Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma.

Journal: Molecular cancer
Published: September 04, 2026

Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma.

Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma.

Journal: Trends in molecular medicine
Published: January 30, 2026

Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma.

Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma.

Journal: Molecular cancer
Published: January 28, 2026

Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression.

Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression.

Journal: Hepatology (Baltimore, Md.)
Published: September 13, 2025

Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.

Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)
Published: June 10, 2025

MASLD/MASH-New mechanisms and treatments.

MASLD/MASH-New mechanisms and treatments.

Journal: Hepatology communications
Published: June 02, 2025

Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response.

Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response.

Journal: Molecular cancer
Published: October 15, 2024

GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in HCC.

GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in HCC.

Journal: Hepatology (Baltimore, Md.)
Published: September 05, 2024

Nuclear localization of BRCA1-associated protein 1 is important in suppressing hepatocellular carcinoma metastasis via CTCF and NRF1/OGT axis.

Nuclear localization of BRCA1-associated protein 1 is important in suppressing hepatocellular carcinoma metastasis via CTCF and NRF1/OGT axis.

Journal: Cell death & disease
Published: August 21, 2024

Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma.

Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma.

Journal: Gut
Published: January 11, 2024

Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma.

Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma.

Journal: Theranostics
Published: July 10, 2023

LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.

LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.

Journal: Hepatology (Baltimore, Md.)
Published: March 07, 2023
Showing 1-12 of 20

Last Updated: 09/26/2026